oxa101 Antibody

What is OXA101 antibody and what research applications is it best suited for?

OXA101 antibody is a research tool designed for the detection and study of OXA-type proteins, which are associated with carbapenem resistance mechanisms. Based on available data on similar antibodies, OXA101 antibody is likely suitable for several research applications including Western blotting (WB), immunohistochemistry on paraffin-embedded tissues (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) .

The antibody enables detection of OXA-type proteins that are critical in antimicrobial resistance research, particularly in studies focusing on Acinetobacter baumannii and other bacterial pathogens carrying OXA-type carbapenemases . When designing experiments, researchers should consider that this antibody is typically used at concentrations of 0.4-4 μg/ml for applications like ICC/IF, with specific dilutions determined by application type and target tissue.

How do OXA-type proteins function in bacterial resistance mechanisms?

OXA-type proteins belong to the class D β-lactamases, specifically the Carbapenem-Hydrolyzing Class D β-lactamases (CHDLs), which are crucial enzymes in bacterial resistance mechanisms. These proteins hydrolyze the β-lactam ring of carbapenem antibiotics, rendering them ineffective .

The OXA family includes several phylogenetic subgroups found in bacterial pathogens:

• OXA-23-like

• OXA-24/40-like

• OXA-58-like

• OXA-51-like

• OXA-143-like

Research has demonstrated that bacteria carrying multiple OXA-type carbapenemase genes simultaneously (particularly combinations of OXA-51-like, OXA-23-like, and OXA-24/40-like) demonstrate enhanced resistance to carbapenems, making these important targets for antibody-based detection in clinical and environmental samples .

What is the difference between OXA101 antibody and other OXA-type antibodies in research applications?

While specific comparative data for OXA101 is limited in the available literature, understanding the general differences between OXA-type antibodies is crucial for experimental design. OXA antibodies typically differ in:

• Epitope specificity: Each antibody targets specific regions within OXA proteins

• Cross-reactivity patterns: Some may recognize multiple OXA variants while others are highly specific

• Application suitability: Performance varies across applications like WB, IHC, and ELISA

Research indicates that antibodies targeting different OXA-types have varying detection capabilities for carbapenemase genes. For instance, in studies of A. baumannii, detection rates using molecular and immunological methods showed significant differences:

These differences highlight the importance of selecting the appropriate antibody based on the specific OXA-type of interest in research .

What are the optimal conditions for using OXA101 antibody in Western blot applications?

For Western blot applications using OXA101 antibody, researchers should implement the following protocol based on data from similar antibodies:

• Sample preparation: Use standard cell lysates or bacterial protein extracts

• Protein loading: 20-50 μg of total protein per lane is recommended

• Separation: 10-12% SDS-PAGE gels provide optimal resolution

• Transfer: Use PVDF membranes for better protein binding

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody: Dilute OXA101 antibody to approximately 0.4 μg/ml in blocking buffer

• Incubation: Overnight at 4°C with gentle rocking

• Detection: HRP-conjugated secondary antibody and ECL detection system

For protein overexpression studies, the antibody has demonstrated effective detection of the target protein in overexpression systems such as transfected HEK-293T cells . When analyzing expected results, researchers should anticipate a band at the predicted molecular weight for OXA-type proteins (typically 25-35 kDa for many OXA-type carbapenemases, though this varies by specific type).

How should researchers optimize immunohistochemistry protocols for OXA101 antibody?

Based on similar antibodies, the following protocol optimizations are recommended for IHC-P applications:

• Tissue preparation: Standard formalin fixation and paraffin embedding

• Section thickness: 4-6 μm sections

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0)

• Blocking: 5-10% normal serum from the same species as the secondary antibody

• Primary antibody dilution: Start with a 1:50 dilution as a baseline

• Incubation time: 1-2 hours at room temperature or overnight at 4°C

• Detection system: Polymer-based detection systems provide enhanced sensitivity

• Counterstaining: Hematoxylin provides good nuclear contrast

When evaluating staining patterns, researchers should compare results across different tissue types. For example, positive staining has been observed in human cerebral cortex and pancreas tissues with similar antibodies at a 1:50 dilution . Tissue-specific optimizations may be necessary, as antibody performance can vary across different tissue types due to fixation differences and target protein expression levels.

What controls should be included when using OXA101 antibody in research?

Proper experimental controls are critical for reliable interpretation of results when using OXA101 antibody:

Positive controls:

• Overexpression systems: Cells transfected with the target OXA gene

• Known positive clinical isolates: Bacterial strains with confirmed expression of OXA-type carbapenemases

• Positive tissue samples: Previously validated tissues known to express the target

Negative controls:

• Vector-only transfected cells: HEK-293T cells transfected with empty vector

• Antibody omission: Samples processed without primary antibody

• Isotype control: Non-specific antibody of the same isotype

• Competitive inhibition: Pre-incubation of antibody with immunizing peptide

Technical validation controls:

• Concentration gradient: Testing multiple antibody dilutions

• Cross-reactivity assessment: Testing against related OXA-type proteins

• Method comparison: Validating results using alternative detection methods (e.g., PCR for gene presence alongside antibody detection of protein)

Implementing these controls helps distinguish true positive signals from background or non-specific binding, particularly important when studying bacterial resistance mechanisms where specific protein identification is crucial.

How can researchers address non-specific binding when using OXA101 antibody?

Non-specific binding is a common challenge with antibodies that can be addressed through several methodological approaches:

• Optimize blocking conditions:

  • Increase blocking time to 2 hours

  • Test alternative blocking agents (BSA, casein, commercial blockers)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

• Adjust antibody concentration and incubation:

  • Perform titration experiments (0.1-5 μg/ml)

  • Reduce incubation temperature to 4°C

  • Add 0.1-1% BSA to antibody dilution buffer

• Increase washing stringency:

  • Add 0.1% Tween-20 to wash buffers

  • Extend washing times and increase washing steps

  • Use higher salt concentration in wash buffers

• Sample-specific optimizations:

  • For bacterial samples, pre-absorb antibody with related bacterial species

  • For tissue samples, use tissue-specific antigen retrieval methods

When analyzing non-specific binding patterns, evaluate whether cross-reactivity occurs with structurally similar proteins. For OXA-type antibodies, cross-reactivity between different OXA variants is possible due to conserved regions, requiring careful interpretation of results, particularly in mixed bacterial populations.

How can OXA101 antibody be adapted for high-throughput screening applications?

Adapting OXA101 antibody for high-throughput screening requires methodological modifications:

• Assay miniaturization:

  • Develop 384-well plate immunoassay formats

  • Reduce antibody concentrations while maintaining signal-to-noise ratio

  • Optimize incubation times for rapid processing

• Automation compatibility:

  • Standardize all buffers and reagents for robotic handling

  • Develop protocols with minimal manual intervention

  • Implement quality control steps at key points

• Detection system optimization:

  • Utilize fluorescent secondary antibodies for multiplexing

  • Implement automated imaging systems with quantitative analysis

  • Consider bead-based assay formats for higher sensitivity

• Validation strategy:

  • Create reference panels of known positive and negative samples

  • Establish Z-factor scores >0.5 for assay robustness

  • Implement statistical methods for hit identification and validation

For bacterial resistance screening applications, researchers have successfully implemented high-throughput approaches combining molecular detection of OXA genes with immunological detection of expressed proteins. This dual approach provides more comprehensive characterization of resistance mechanisms compared to either method alone .

What methodologies enable quantitative analysis of OXA protein expression using OXA101 antibody?

Quantitative analysis of OXA protein expression requires specific methodological considerations:

• Quantitative Western blotting:

  • Include known concentration standards of recombinant protein

  • Utilize LI-COR or similar fluorescent detection systems

  • Apply densitometry with appropriate software (ImageJ, etc.)

  • Normalize to appropriate housekeeping proteins

• ELISA development:

  • Develop sandwich ELISA using OXA101 as capture or detection antibody

  • Generate standard curves using purified recombinant protein

  • Implement four-parameter logistic regression for analysis

  • Establish limits of detection and quantification

• Flow cytometry for bacterial samples:

  • Optimize fixation and permeabilization protocols

  • Use fluorophore-conjugated secondary antibodies

  • Include fluorescence calibration beads

  • Analyze median fluorescence intensity values

• Image-based quantification:

  • Implement immunofluorescence with standardized exposure settings

  • Use appropriate software for automated image analysis

  • Include internal calibration controls in each image

  • Apply background correction algorithms

When interpreting quantitative data, researchers should consider that OXA protein expression levels vary significantly based on environmental conditions, antibiotic pressure, and bacterial growth phase. Studies of OXA-type carbapenemases have shown differential expression patterns between clinical and environmental isolates, suggesting complex regulatory mechanisms worthy of investigation .

How does OXA101 antibody performance compare with molecular detection methods for OXA genes?

Understanding the relationship between antibody-based protein detection and molecular detection of genes is crucial for comprehensive research:

Studies of OXA-type carbapenemases have shown that while genes may be detected by PCR, protein expression levels can vary significantly based on regulatory mechanisms and environmental conditions . This discordance highlights the value of using antibody-based detection alongside molecular methods. For example, research has demonstrated that all A. baumannii isolates carrying the blaOXA-51-like gene may not equally express the corresponding protein, affecting phenotypic resistance patterns.

What are the considerations when comparing results across different antibodies targeting the same OXA-type proteins?

When comparing results obtained using different antibodies targeting the same OXA proteins, researchers should consider:

• Epitope differences:

  • Antibodies targeting different epitopes may yield varying results

  • Conformational versus linear epitopes affect detection in different applications

  • N-terminal versus C-terminal targeting affects detection of truncated forms

• Methodological standardization:

  • Harmonize protocols when comparing antibodies

  • Use consistent sample preparation methods

  • Apply identical detection systems and imaging parameters

• Cross-reactivity profiles:

  • Evaluate specificity against related OXA variants

  • Test against non-OXA β-lactamases

  • Consider evolutionary relationships between targets

• Application-specific performance:

  • An antibody performing well in Western blot may underperform in IHC

  • Fixation sensitivity varies between antibodies

  • Native versus denatured protein detection capabilities differ

Research has shown that antibodies against OXA-type carbapenemases can exhibit variable cross-reactivity patterns, particularly against closely related variants within the same phylogenetic subgroup. For example, antibodies targeted against OXA-23-like proteins may show different levels of cross-reactivity with OXA-24/40-like proteins based on their specific epitope targets .

What are the emerging applications of OXA antibodies in studying antimicrobial resistance mechanisms?

Emerging research applications for OXA antibodies are expanding our understanding of antimicrobial resistance:

• Host-pathogen interaction studies:

  • Investigating the role of OXA proteins in bacterial virulence

  • Examining host immune responses to OXA-producing bacteria

  • Studying the impact of OXA expression on bacterial fitness

• Environmental surveillance:

  • Monitoring OXA-type carbapenemases in hospital environments

  • Tracking resistance gene spread in community settings

  • Evaluating persistence of resistant bacteria on surfaces

• Combined multi-omics approaches:

  • Integrating proteomics with genomics and transcriptomics

  • Correlating OXA protein expression with resistance phenotypes

  • Studying regulatory networks controlling OXA expression

• Novel therapeutic strategies:

  • Developing inhibitors targeting OXA-type carbapenemases

  • Evaluating antibody-antibiotic conjugates for targeted therapy

  • Exploring immunotherapeutic approaches against resistant bacteria

Studies have demonstrated the significance of environmental reservoirs for antimicrobial resistance genes, with hospital surfaces harboring MDR and XDR bacterial strains carrying multiple OXA-type carbapenemase genes. Research shows that intensive care units (52.4%) and burn units (15.6%) are particularly prone to contamination with resistant A. baumannii strains carrying OXA genes, highlighting the importance of environmental surveillance in infection control .